**ORIGINAL ARTICLE**



# **Probing the interaction of ciprofol and human serum albumin using multiple spectroscopies**

**Qiao Pan<sup>1</sup> · Chengfeng Yao2 · Yulin Zhu1 · Shujun Shang1**

Received: 25 February 2024 / Accepted: 23 March 2024 / Published online: 18 April 2024 © The Author(s), under exclusive licence to Springer Nature B.V. 2024

#### **Abstract**

The interaction between ciprofol and human serum albumin (HSA) was studied using spectroscopy-based approaches at diferent temperatures under simulated physiological conditions *in vitro*. Quenching of intrinsic Trp fuorescence of HSA with increasing ciprofol concentration is the actuating tool in the analysis. Experimental results proved that ciprofol quenched the intrinsic fuorescence of HSA through a static quenching mechanism. The thermodynamic parameters  $(\Delta G = -2.35 \times 10^4 \text{ J} \cdot \text{mol}^{-1}, \Delta S = -131 \text{ J} \cdot \text{mol}^{-1} \cdot \text{K}^{-1}, \text{ and } \Delta H = -6.39 \times 10^4 \text{ J} \cdot \text{mol}^{-1} \text{ at } 310 \text{ K}), \text{ binding sites } (n = 0.83), \text{ and }$ binding constant ( $K_A$  = 9.12 × 10<sup>3</sup> M<sup>-1</sup>) indicated that hydrogen bond and van der Waals forces played a major role in the HSA-ciprofol association with weak binding force. Furthermore, the circular dichroism, synchronous, and three-dimensional fuorescence spectral results indicated adaptive structural changes of HSA in the presence of ciprofol. In addition, the efect of some common metal ions on the binding between ciprofol and HSA was examined, and  $Fe<sup>3+</sup>$  and  $Hg<sup>2+</sup>$  were proven to help prolong the storage time and improve the drug efficacy. The study provides accurate and full basic data for clarifying the binding mechanisms of ciprofol with HSA and helps understand its efect on protein function during the blood transportation process and activity in vivo.

**Keywords** Ciprofol · Human serum albumin · Interaction mechanism · Spectroscopy

# **Introduction**

Ciprofol is a novel intravenous anesthetic compound closely resembling propofol in chemical structure. It exhibits rapid onset and recovery in preclinical studies[[1\]](#page-6-0). Furthermore, ciprofol exhibited a lower free drug concentration in the aqueous phase than propofol under identical conditions and concentrations when analyzed using the "ultrafltration method," indicating a potential reduction or elimination of pain upon injection[\[2](#page-6-1)].

Serum albumin is the primary soluble protein in the circulatory system that plays various physiological roles, such as regulating blood osmotic pressure and pH, and acting as

Qiao Pan and Chengfeng Yao have contributed equally to this work.

<sup>2</sup> Department of Anesthesiology, Yantai Hospital of Traditional Chinese Medicine, Yantai 264000, China a carrier for transporting numerous endogenous and exogenous substances like drugs, amino acids, and fatty acids[\[3](#page-6-2)]. The interaction between drugs and serum albumin signifcantly infuences the way drugs are distributed and their efectiveness[[4\]](#page-6-3). Studying how pharmaceuticals interact with serum albumin is crucial for understanding drug nature, pharmacokinetics, and the correlation between drug structures and functions. Human serum albumin (HSA) consists of three structurally similar, mainly helical domains (I, II, and III), each with two subdomains (A and B)[\[5\]](#page-6-4). The main drug-binding areas on albumin are found in hydrophobic pockets in subdomains IIA and IIIA, which share similar chemical characteristics[[6\]](#page-6-5). Consequently, the interaction between medicines and serum albumin consistently leads to interference with the binding of other pharmaceuticals due to overlapping binding sites or conformational changes.

Understanding the interactions between medications and serum albumin is crucial for comprehending pharmacokinetics and pharmacodynamics. A thorough study was conducted here to analyze the binding characteristics of ciprofol to HSA under standard physiological settings. We analyzed the binding information of HSA using various spectroscopic

 $\boxtimes$  Shujun Shang ssjyts@126.com

<sup>&</sup>lt;sup>1</sup> Department of Anesthesiology, Yantaishan Hospital, Yantai 264000, China

approaches to study quenching mechanisms, thermodynamic characteristics, binding modes, and conformation changes. The work offers precise and comprehensive foundational data to elucidate the binding methods of ciprofol with HSA. It aids in understanding the impact of drugs on protein function during the transportation processes in vivo.

# **Materials and methods**

## **Materials**

HSA (purity>96%) was bought from Sigma Chemical Co. (St. Louis, USA) and was utilized without further purifcation. The HSA solutions were made in a pH 7.4 Tris−HCl buffer solution with a concentration of 0.2 mol/L, supplemented with NaCl at a concentration of 0.1 mol/L to maintain the solution's ionic strength. The HSA stock solution was diluted in Tris− HCl bufer right before use. Ciprofol with a purity of over 98% and all other reagents were bought from J&K Scientifc Ltd. (Beijing, China). Ultrapure water was utilized in all the studies.

#### **Fluorescence spectroscopy**

The fuorescence spectra were measured using an F4500 spectrofuorophotometer (Hitachi, Tokyo, Japan) at various temperatures with slit widths set at 5 nm/5 nm. The excitation wavelength used was 295 nm for the excitation of Trp, and the emission spectra were measured within the range of 290 to 420 nm.

The synchronous fuorescence spectra were measured with a  $\Delta$ -value of 15 or 60 nm between excitation and emission wavelengths. The emission and excitation bandwidths were both set at 5 nm. The spectra of HSA were recorded in the absence and presence of varying concentrations of ciprofol under similar conditions to steady-state fuorescence measurements.

Three-dimensional fuorescence spectra were conducted with the emission wavelength ranging from 200 to 500 nm. The excitation wavelength started at 200 nm with increments of 5 nm, ending at 400 nm. Other scanning parameters

were identical to those used for the fuorescence quenching spectra.

#### **UV–vis spectroscopy**

 $UV - vis$  absorption spectroscopy was conducted using a UV-2450 UV −vis spectrophotometer from Shimadzu in Tokyo, Japan, which was ftted with a 1.0 cm quartz cell. The wavelength range was 290 to 420 nm.

#### **Circular dichroism spectroscopy**

Circular dichroism (CD) measurements were conducted with a JASCO J-815 automatic recording spectrophotometer from Tokyo, Japan, in a 1 cm quartz cell at room temperature. The concentrations of HSA and ciprofol were set at  $2 \times 10^{-7}$  and 1× 10−6 M, respectively. Each spectrum was the mean of three consecutive scans. CD spectra were measured between 200 and 250 nm. The CDpro software suite (available at [https://www.bmb.colostate.edu/cdpro/\)](https://www.bmb.colostate.edu/cdpro/) was utilized to determine the secondary structural composition of HSA.

# **Results and discussion**

Fluorescence measurements of macromolecules can provide insights into the interaction of small-molecule compounds with proteins, including details regarding the binding mechanism, mode, constant, sites, and intermolecular distances[[7,](#page-6-6) [8](#page-6-7)]. Figure [1](#page-1-0) displays the fuorescence emission spectra of HSA at pH 7.40 in the presence of ciprofol. When excited at 295 nm, HSA exhibited a prominent fuorescence emission peak at 336 nm. The fuorescence intensity of HSA diminished consistently as the concentration of ciprofol increased. Because the absorbance at both excitation and emission wavelengths of the interaction system was not strong enough (higher than 0.1), the decreased fuorescence intensity was not likely due to the inner filter effects but the interaction with ciprofol, indicating microenvironmental changes of Trp. The fuorescence quenching data were evaluated using the Stern–Volmer equation to confrm the quenching mechanism[[9,](#page-6-8) [10\]](#page-6-9):

<span id="page-1-0"></span>



#### $F0/F = 1 + Kq\tau 0[Q] = 1 + KSV[Q]$

where  $F_0$  and  $F$  are the fluorescence intensity before and after the addition of the quencher, respectively, and  $K_a$ ,  $K_{SV}$ ,  $\tau_0$ , and [*Q*] are the quenching rate constant, the Stern–Volmer quenching constant, the average lifetime of HSA ( $\tau_0$ = 10<sup>-8</sup> s) and the drug concentration, respectively. Table [1](#page-2-0) displays the  $K_{SV}$  and  $K_a$  values at various temperatures. The  $K_{SV}$  values decreased with rising temperatures, indicating that the HSA-ciprofol quenching mechanism was static based on fuorescence quenching mechanisms (Fig. [2](#page-2-1)).

The binding constant  $(K_A)$  and number of binding sites (*n*) for the ciprofol–HSA were calculated by using the following equation[\[11](#page-6-10), [12\]](#page-6-11):

 $\frac{1g}{F} \frac{F_0 - F}{F} = \frac{1g}{K_A} + n \lg{Q}.$ 

The binding constant increases as the temperature falls, but the value of (*n*) remains constant at diferent temperatures. The results suggest that a stable HSA-ciprofol complex at 310 K (physiological temperature) may be more stable than at a lower temperature. Table [1](#page-2-0) displays the binding properties acquired at various temperatures. The  $n$  and  $K_A$ values, derived from the linear regression equation of log  $(F_0-F)/F$  versus log [*Q*], were determined to be 0.83 and  $9.12 \times 10^3$  M<sup>-1</sup>, respectively. These findings suggest weak binding forces with fewer than one binding site at physiological temperature[[8,](#page-6-7) [13,](#page-6-12) [14\]](#page-6-13).

The determination of the acting force between ciprofol and HSA.

The following equations provided were used to assess the alterations in entropy, enthalpy, and free energy at diferent temperatures[[15–](#page-6-14)[17\]](#page-6-15):

$$
\ln\left(\frac{K_2}{K_1}\right) = \frac{\Delta H}{R}\left(\frac{1}{T_1} - \frac{1}{T_2}\right)
$$

## $ΔG = ΔH - TΔS = -RT ln K$

where  $\Delta H$ ,  $\Delta G$ , and  $\Delta S$  denote enthalpy change, free enthalpy change, and entropy change, respectively. *K* represents the binding constant at the corresponding temperature. *R* represents the gas constant with a value of 8.314 J/ mol/K, whereas *T* is the experimental temperature in Kelvin. A direct correlation was noted between the connection of



<span id="page-2-1"></span>**Fig. 2** (**A**) Stern–Volmer and (**B**) Hill plots for HSA-ciprofol at different temperatures. Conditions: pH 7.4; c(HSA) =  $1 \times 10^{-6}$  M

ln*K* with 1/*T*, with a slope equivalent to the  $\Delta H/R$  value (Fig. [3\)](#page-3-0). When Δ*H* is negative and Δ*S* is positive, the major force is electrostatic interactions. When Δ*H* is negative and Δ*S* is negative, the main force is van der Waals or hydrogen bonding. When Δ*H* and Δ*S* are both positive, the main force is hydrophobic interactions. The table in Table [1](#page-2-0) displays the values of  $\Delta H$ ,  $\Delta G$ , and  $\Delta S$ . The negative values of  $\Delta H$ and Δ*S* indicate that hydrogen bonding and van der Waals forces are the major binding forces in the binding process.

<span id="page-2-0"></span>**Table 1** Stern–Volmer quenching constants, binding parameters, and thermodynamic parameters of HSA-ciprofol system at diferent temperatures

T(K)	Stern-Volmer quenching constants			Binding parameters			Thermodynamic parameters		
	$K_0(M^{-1} s^{-1})$ $K_{SV} (M^{-1})$		Pearson's r $K_A (M^{-1})$ n			Pearson's r	$\Delta G^{\circ}(\text{J}\cdot\text{mol}^{-1})$	$\Delta S^{\circ}(\text{J}\cdot \text{mol}^{-1}\cdot \text{K}^{-1})$	$\Delta H(\text{J} \cdot \text{mol}^{-1})$
280	$1.43 \times 10^{13}$	$1.43 \times 10^{5}$	0.9987	$1.29 \times 10^{5}$	0.99	0.9986	$-2.74 \times 10^4$	$=$	-
295	$9.69 \times 10^{12}$	$9.69 \times 10^{4}$	0.9977	$2.69 \times 10^{4}$	0.88	0.9995	$-2.50 \times 10^{4}$	$-131$	$-6.39 \times 10^{4}$
310	$5.91 \times 10^{12}$	$5.91 \times 10^{4}$	0.9919	$9.12 \times 10^3$	0.83	0.9939	$-2.35 \times 10^{4}$	-	-



<span id="page-3-0"></span>Fig. 3 van't Hoff plot of the HSA-ciprofol system

#### **Energy transfer between ciprofol and HSA**

Fluorescence resonance energy transfer (FRET) theory allows for the calculation of energy transfer parameters using the following equations. The efficiency of energy transfer  $(E)$  can be determined as [\[18\]](#page-6-16):

 $E = 1 - \frac{F}{F_0} = \frac{R_0^6}{R_0^6 + r^6}$ 

where  $E$  is the energy transfer efficiency between the donor and acceptor, and *r* is the binding distance between them. The equation for  $R_0$ , the critical distance, where the transfer efficiency is 50%, is as follows[[19](#page-6-17)]:

 $R_0^6 = 8.8 \times 10^{-25} k^2 N^{-4} \Phi J,$ 

where  $k^2$  represents the orientation factor for the donor and acceptor of dipoles, *N* represents the refractive index of the medium, and *Φ* represents the fuorescence quantum yield of the donor. *J* represents the overlap integral of the fuorescence emission spectrum of the donor and the absorption spectrum of the acceptor and can be calculated using the following formula[[20](#page-6-18)]:

 $J = \frac{\int F(\lambda)\varepsilon(\lambda)\lambda^4\Delta\lambda}{\int F(\lambda)\Delta\lambda}$ .

 $F(\lambda)$  represents the fluorescence intensity of HSA at wavelength  $\lambda$ , while  $\varepsilon(\lambda)$  stands for the extinction coefficient of the acceptor at  $\lambda$ . Figure S1 demonstrates a notable overlap between the emission spectrum of HSA and the absorption spectrum of ciprofol, indicating the potential for energy transfer between both molecules. For HSA, the values are  $k^2 = 2/3$ ,  $N = 1.336$ , and  $\Phi = 0.118[21]$  $\Phi = 0.118[21]$  $\Phi = 0.118[21]$ . The equations provided yield the following results: *J*=1.18 × 10<sup>-14</sup> cm<sup>3</sup> L mol<sup>-1</sup>, *E* = 0.098, *R*<sub>0</sub> = 2.67 nm, and  $r = 2.98$  nm. The *r* value falls within the range of 2–8 nm, with  $0.5R_0 < r < 1.5R_0$ , suggesting an interaction between ciprofol and HSA.



<span id="page-3-1"></span>**Fig. 4** (**A**) CD spectra of HSA ( $2 \times 10^{-7}$  M) in the absence and presence of ciprofol  $(1 \times 10^{-6}$  M). (**B**) The corresponding secondary structural fractions

# **Conformational studies by circular dichroism, 3D, and synchronous fuorescence spectroscopy**

A circular dichroism (CD) analysis was conducted to investigate the protein structures. CD spectra of HSA and HSA–ciprofol were obtained using a CD spectrometer at room temperature within the wavelength range of 190 to 260 nm. The samples were examined in the far-ultraviolet range using a quartz cuvette with a route length of 1 cm. Figure [4](#page-3-1) displays the second structure of the HSA curve and corresponding data. The CD spectra of HSA show two wide dip bands at 208 and 222 nm, indicating the transition of  $\pi - \pi^*$  and  $n - \pi^*$  of the α-helical structure of the HSA molecule. Alterations in the ellipticity at 208 and 222 nm are valuable indicators for observing changes in  $\alpha$ -helical content [[22\]](#page-6-20). The  $\alpha$ -helix structure in HSA was 55%, closely matching Song et al.'s fndings[\[23\]](#page-6-21). An increase in ciprofol concentration led to a decrease in the α-helix content of HSA compared to native HSA, indicating a change in the secondary structure of HSA due to the interaction with ciprofol. The β-turn content in HSA rose with the addition of ciprofol. The results show that ciprofol was strongly bound to HSA, which caused a change in its structure. The observed decrease in  $\alpha$ -helical content and increase in β-content and random coiling indicate the disruption of the hydrogen bond network, which previously upheld the helical structure and overall skeleton. Due to the structural stability of  $β$ -sheets compared to α-helices, these changes in secondary structure may be linked to adaptive and irreversible modifcations that counteract the disturbance generated by ciprofol[[24](#page-6-22)].

We further investigated HSA conformational changes using 3D fuorescence spectroscopy. Comparative data can provide insights into how the protein's structure is afected due to microenvironmental changes. Alterations in the excitation or emission wavelength around the fuorescence peak, the introduction of new peaks, or the vanishing of existing peaks might provide valuable insights into the protein's structural changes. Excitation of HSA at 280 nm reveals the intrinsic fuorescence of Trp and Tyr residues, with minimal contribution from Phe residues. Figure [5](#page-4-0) displays the 3D spectra and contour maps of HSA−ciprofol complexes, while Table [2](#page-4-1) shows the spectral parameters obtained from these spectra. Peak I represents the spectrum characteristics of the fuorophore residues. Comparing it with the absorption spectrum of HSA, we may deduce that the peak at 280 nm is due to  $\pi - \pi^*$  transitions of the aromatic amino



<span id="page-4-0"></span>**Fig. 5** 3D fuorescence spectra of pure HSA (**A**) and HSA-ciprofol (**B**). Conditions: pH 7.4; c(HSA)=1× 10−6 M; c(ciprofol): 1× 10−5 M

<span id="page-4-1"></span>

acids. Peak II displays the protein's skeletal structural information. There was no Stokes shift but a signifcant drop in intensity for both peaks, suggesting changes in the surroundings of both fuorophores and the polypeptide backbone.

Synchronous fuorescence screening is a crucial approach for gathering information about the chemical environment and its connection with chromophore molecules. Synchronous fuorescence spectroscopy was used here to investigate the impact of ciprofol binding on the conformation of HSA fuorophores and the molecular environment. The synchronous fuorescence spectra reveal precise details about the microenvironment of Trp or Tyr residues when measured at 60 or 15 nm[[25\]](#page-6-23). Synchronous fuorescence spectra of HSA were observed both with and without ciprofol. Figure [6A](#page-5-0) shows only a 2 nm shift in the peak wavelength of Trp, suggesting slight alterations in the surrounding environment of the Trp residue. The Tyr synchronous fuorescence range remained constant, indicating no shift in polarity around the Tyr residue (Fig. [6](#page-5-0)B).

#### **Efect of metal ions on HSA‑ciprofol association**

Plasma reportedly contains metal ions that can uphold the regular structures and physiological functions of proteins. Metal ions are necessary for humans and animals, playing a crucial structural function in many protein-based coordination connections[[26](#page-6-24)]. Metal ions in plasma can infuence the interaction of medicines with HSA. Cation concentrations were set at  $1.0 \times 10^{-5}$  M, and the anions were all chloride ions, which did not infuence protein fuorescence. The binding constants of ciprofol with HSA at 310 K are included in Table  $3$ . As shown in Table  $3$ , The binding affinities between ciprofol and HSA were altered to diferent extents in the presence of metal ions, possibly due to conformational alterations around the binding sites. Reduced binding constants manifest decreased storage duration, which may increase harmful effects. Increased binding constants usually mean that the drug concentration in the circulation is bufered and its duration in the plasma is prolonged. Hence, the intended therapeutic outcome is attained. It can be inferred

<span id="page-5-0"></span>**Fig. 6** Synchronous fuorescence spectra of ciprofol with HSA with (**A**)  $\Delta\lambda = 15$  nm or (**B**)  $\Delta\lambda$  = 60 nm at 310 K. Concentrations of the HSA and ciprofol are in line with Fig. [1](#page-1-0)



<span id="page-5-1"></span>**Table 3** Efects of common metal ions on the binding constants of HSA and ciprofol at body temperature (310 K)

Systems	$K_{\rm a}$ (M <sup>-1</sup> )	$K_{\rm a}/K_{\rm o}$	Pearson's r
HSA-ciprofol	$9.12 \times 10^{3}$	1.00	0.9932
HSA-ciprofol-K <sup>+</sup>	$1.02 \times 10^{4}$	1.11	0.9975
HSA-ciprofol-Li <sup>+</sup>	$1.07 \times 10^{4}$	1.17	0.9853
$HSA$ -ciprofol- $Cu^{2+}$	$8.63 \times 10^{3}$	0.95	0.9532
HSA-ciprofol-Fe <sup>3+</sup>	$1.69 \times 10^{4}$	1.85	0.9975
$HSA$ -ciprofol-Ba <sup>2+</sup>	$1.04 \times 10^{4}$	1.14	0.9837
$HSA$ -ciprofol- $Sn^{2+}$	$9.34 \times 10^3$	1.02	0.9854
$HSA$ -ciprofol- $Mn^{2+}$	$8.77 \times 10^{3}$	0.96	0.9543
$HSA$ -ciprofol-Zn <sup>2+</sup>	$1.04 \times 10^{4}$	1.14	0.9965
HSA-ciprofol- $Ca^{2+}$	$9.04 \times 10^3$	0.99	0.9855
$HSA$ -ciprofol- $Hg^{2+}$	$1.52 \times 10^{4}$	1.67	0.9533

from the results that the elevated binding constants of HSAciprofol in the presence of  $Fe^{3+}$  and  $Hg^{2+}$  extend the drug's storage period in blood plasma and improve its maximal effectiveness.

## **Conclusions**

In this research, various spectroscopic techniques have been used to explore the binding mechanisms of ciprofol to HSA. A static quenching process of the quenching mechanism of HSA induced by ciprofol has been revealed. The thermodynamic parameters manifested the critical role of hydrogen bond and van der Waals forces overwhelmed in keeping the stability of the ciprofol–HSA complex. The distance of ciprofol to HSA was close enough (*r*=2.98 nm) to realize nonradiative energy transfer from Trp to ciprofol. As was illustrated by CD, 3D, and synchronous fuorescence results, the ciprofol binding induced microenvironmental changes of the protein and adaptive secondary structural changes featured by decreased  $\alpha$ -helical content. Besides, Fe<sup>3+</sup> and Hg<sup>2+</sup> ions could enhance the ciprofol binding and prolong the blood storage time, which may improve the curative efect. This



study is expected to facilitate further understanding of the interaction mechanism of HSA with ciprofol, which helps to provide theoretical foundations for ciprofol as an alternative to other phenol derivatives, such as propofol or fospropofol.

**Supplementary Information** The online version contains supplementary material available at<https://doi.org/10.1007/s10847-024-01241-5>.

**Author contributions** Q.P. and C.Y. wrote the main manuscript text and Y.Z. prepared all the fgures. S.S. guided the work. All authors reviewed the manuscript.

#### **Declarations**

**Competing interests** The authors declare no competing interests.

## **References**

- <span id="page-6-0"></span>1. Hung, K.-C., Chen, J.-Y., Wu, S.-C., Huang, P.-Y., Wu, J.-Y., Liu, T.-H., Liu, C.-C., Chen, I.-W., Sun, C.-K.: A systematic review and meta-analysis comparing the efficacy and safety of ciprofol (HSK3486) versus propofol for anesthetic induction and non-ICU sedation. Front. Pharmacol. **14**, 1225288 (2023)
- <span id="page-6-1"></span>2. Teng, Y., Ou, M., Wang, X., Zhang, W., Liu, X., Liang, Y., Li, K., Wang, Y., Ouyang, W., Weng, H.: Efficacy and safety of ciprofol for the sedation/anesthesia in patients undergoing colonoscopy: phase IIa and IIb multi-center clinical trials. Eur. J. Pharm. Sci. **164**, 105904 (2021)
- <span id="page-6-2"></span>3. Zhao, X., Li, P., Song, S., Wang, H., Zhao, L., Zong, W., Zhang, H., Qu, G., Hu, L., Cai, Z.: Molecular structural heterogeneity of bisphenols governs their serum albumin binding. Sci. Total Environ. (2021).<https://doi.org/10.1016/j.scitotenv.2021.146499>
- <span id="page-6-3"></span>4. Sułkowska, A.: Interaction of drugs with bovine and human serum albumin. J. Mol. Struct. **614**, 227–232 (2002)
- <span id="page-6-4"></span>5. Zhao, X., Sheng, F., Zheng, J., Liu, R.: Composition and stability of anthocyanins from purple solanum tuberosum and their protective infuence on Cr(VI) targeted to bovine serum albumin. J. Agric. Food Chem. **59**, 7902–7909 (2011)
- <span id="page-6-5"></span>6. Lebofe, L., di Masi, A., Polticelli, F., Trezza, V., Ascenzi, P.: Structural basis of drug recognition by human serum albumin. Current Med. Chem. (2019). [https://doi.org/10.2174/0929867326](https://doi.org/10.2174/0929867326666190320105316) [666190320105316](https://doi.org/10.2174/0929867326666190320105316)
- <span id="page-6-6"></span>7. Zhao, X., Hao, F., Lu, D., Liu, W., Zhou, Q., Jiang, G.: Infuence of the surface functional group density on the carbon-nanotubeinduced α-chymotrypsin structure and activity alterations. ACS Appl. Mater. Interf. **7**, 18880–18890 (2015)
- <span id="page-6-7"></span>8. Mokaberi, P., Babayan-Mashhadi, F., Amiri Tehrani Zadeh, Z., Saberi, M.R., Chamani, J.: Analysis of the interaction behavior between Nano-Curcumin and two human serum proteins: combining spectroscopy and molecular stimulation to understand proteinprotein interaction. J. Biomol. Struct. Dynam. **39**, 3358–3377 (2021)
- <span id="page-6-8"></span>9. Zhao, X.C., Liu, R.T., Chi, Z.X., Teng, Y., Qin, P.F.: New insights into the behavior of bovine serum albumin adsorbed onto carbon nanotubes: comprehensive spectroscopic studies. J. Phys. Chem. B **114**, 5625–5631 (2010)
- <span id="page-6-9"></span>10. Zhu, Y., Liu, G., Liu, A., Yu, L.: biophysical study on the interaction of dexmedetomidine and serum protein. Lat. Am. J. Pharm. **33**, 1669–1677 (2014)
- <span id="page-6-10"></span>11. Zhao, X., Lu, D., Hao, F., Liu, R.: Exploring the diameter and surface dependent conformational changes in carbon

nanotube-protein corona and the related cytotoxicity. J. Hazard. Mater. **292**, 98–107 (2015)

- <span id="page-6-11"></span>12. Chanphai, P., Tajmir-Riahi, H.: Tea polyphenols bind serum albumins: a potential application for polyphenol delivery. Food Hydrocoll. **89**, 461–467 (2019)
- <span id="page-6-12"></span>13. Rahnama, E., Mahmoodian-Moghaddam, M., Khorsand-Ahmadi, S., Saberi, M.R., Chamani, J.: Binding site identifcation of metformin to human serum albumin and glycated human serum albumin by spectroscopic and molecular modeling techniques: a comparison study. J. Biomol. Struct. Dyn. **33**, 513–533 (2015)
- <span id="page-6-13"></span>14. Danesh, N., Navaee Sedighi, Z., Beigoli, S., Sharif-Rad, A., Saberi, M.R., Chamani, J.: Determining the binding site and binding affinity of estradiol to human serum albumin and holotransferrin: fuorescence spectroscopic, isothermal titration calorimetry and molecular modeling approaches. J. Biomol. Struct. Dyn. **36**, 1747–1763 (2018)
- <span id="page-6-14"></span>15. Beigoli, S., Sharif Rad, A., Askari, A., Assaran Darban, R., Chamani, J.: Isothermal titration calorimetry and stopped fow circular dichroism investigations of the interaction between lomefoxacin and human serum albumin in the presence of amino acids. J. Biomol. Struct. Dyn. **37**, 2265–2282 (2019)
- 16. Kamshad, M., Jahanshah Talab, M., Beigoli, S., Sharifrad, A., Chamani, J.: Use of spectroscopic and zeta potential techniques to study the interaction between lysozyme and curcumin in the presence of silver nanoparticles at diferent sizes. J. Biomol. Struct. Dyn. **37**, 2030–2040 (2019)
- <span id="page-6-15"></span>17. Sadeghzadeh, F., Entezari, A.A., Behzadian, K., Habibi, K., Amiri-Tehranizadeh, Z., Asoodeh, A., Saberi, M.R., Chamani, J.: Characterizing the binding of angiotensin converting enzyme I inhibitory peptide to human hemoglobin: Infuence of electromagnetic felds. Protein Pept. Lett. **27**, 1007–1021 (2020)
- <span id="page-6-16"></span>18. Chamani, J.: Energetic domains analysis of bovine α-lactalbumin upon interaction with copper and dodecyl trimethylammonium bromide. J. Mol. Struct. **979**, 227–234 (2010)
- <span id="page-6-17"></span>19. Cheng, Z.: Comparative studies on the interactions of honokiol and magnolol with human serum albumin. J. Pharm. Biomed. Anal. **66**, 240–251 (2012)
- <span id="page-6-18"></span>20. Meti, M.D., Byadagi, K.S., Nandibewoor, S.T., Chimatadar, S.A.: Multi-spectral characterization & efect of metal ions on the binding of bovine serum albumin upon interaction with a lincosamide antibiotic drug, clindamycin phosphate. J. Photochem. Photobiol., B **138**, 324–330 (2014)
- <span id="page-6-19"></span>21. Lu, D.W., Zhao, X.C., Zhao, Y.C., Zhang, B.C., Zhang, B., Geng, M.Y., Liu, R.T.: Binding of Sudan II and Sudan IV to bovine serum albumin: comparison studies. Food Chem. Toxicol. **49**, 3158–3164 (2011)
- <span id="page-6-20"></span>22. Zhao, X., Lu, D., Liu, Q.S., Li, Y., Feng, R., Hao, F., Qu, G., Zhou, Q., Jiang, G.: Hematological effects of gold nanorods on erythrocytes: hemolysis and hemoglobin conformational and functional changes. Adv. Sci. **4**, 1700296 (2017)
- <span id="page-6-21"></span>23. Song, S., Li, Y., Liu, Q.S., Wang, H., Li, P., Shi, J., Hu, L., Zhang, H., Liu, Y., Li, K.: Interaction of mercury ion (Hg2+) with blood and cytotoxicity attenuation by serum albumin binding. J. Hazard. Mater. (2021). <https://doi.org/10.1016/j.jhazmat.2021.125158>
- <span id="page-6-22"></span>24. Leuenberger, P., Ganscha, S., Kahraman, A., Cappelletti, V., Boersema, P.J., von Mering, C., Claassen, M., Picotti, P.: Cellwide analysis of protein thermal unfolding reveals determinants of thermostability. Science **355**, eaai825 (2017)
- <span id="page-6-23"></span>25. Zhao, Z., Li, H., Yao, J., Lan, J., Bao, Y., Zhao, L., Zong, W., Zhang, Q., Hollert, H., Zhao, X.: Binding of tetrabromobisphenol A and S to human serum albumin is weakened by coexisting nanoplastics and environmental kosmotropes. Environ. Sci. Technol. **57**, 4464–4470 (2023)
- <span id="page-6-24"></span>26. Zhao, Z., Yao, J., Li, H., Lan, J., Hollert, H., Zhao, X.: Interaction of polystyrene nanoplastics and hemoglobin is determined by both

particle curvature and available surface area. Sci. Total Environ. **899**, 165617 (2023)

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional afliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.